Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma — Stella

Home/Relapsed/Refractory Multiple Myeloma(MM)/LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma

View on ClinicalTrials.gov

Recruiting

Back to Relapsed/Refractory Multiple Myeloma(MM) trials

LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(4 sites)

China

Beijing Boren Hospital, Beijing

Institute of Hematology & Blood Diseases Hospital, Tianjin

Institute of Hematology & Blood Diseases Hospital, Tianjin

Wuhan Union Hospital, Wuhan

Key details

Sponsor

Nanjing Legend Biotech Co.

Collaborators

Institute of Hematology & Blood Diseases Hospital, China

Enrollment target

~35 participants

Started

September 2025

Primary completion

February 2028

Age range

18 Years and older

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.